A new white paper has been published by leaders in the cannabis field, showcasing how to maximise clinical research and improve patient access to medical cannabis in the UK.
Following the approval of medical cannabis in the UK in November 2018, only two patients have gained access to full extract cannabis medicine through an NHS prescription. The authors have produced the white paper, ‘Medical cannabis in the UK: From principle to practice’ to help reduce the disparity in demand and supply.
The medical cannabis white paper puts forward potential solutions for healthcare workers prescribing medical cannabis, and for regulators in responding to the demand for access in the face of limited research for specific conditions – suggesting how to accelerate the integration of medical cannabis into UK healthcare.
Sativa Group Plc (NEX:SATI) is the UK’s leading quoted CBD Wellness and medicinal cannabis group with five operating subsidiaries. Goodbody Botanicals provides CBD products online and to retail markets including pharmacies, wellness stores and grocers. Goodbody Wellness is a high-street retail brand with dedicated CBD Wellness stores providing a premium shopping experience to consumers. Tessellate Collective is a direct-selling network marketing platform servicing consumers at home. Phytovista laboratories provides independent testing of CBD products to both external customers and fellow Group businesses. Sativa Grow holds a Controlled Drug licence and cultivates cannabis plants to fulfill its partnership agreement with King’s College London to research the impact of cannabinoids on inflammation and respiratory conditions.